[{"orgOrder":0,"company":"Captain T Cell","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River, Captain T Cell Sign Plasmid DNA & Viral Vector Production Program Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"TCR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Captain T Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Captain T Cell \/ Charles River Laboratories, inc","highestDevelopmentStatusID":"4","companyTruncated":"Captain T Cell \/ Charles River Laboratories, inc"}]

Find Clinical Drug Pipeline Developments & Deals by Captain T Cell

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : Captain T Cell will have access to established plasmid and viral vector CDMO capabilities and advisory services ahead of its plan to manufacture a TCR-T cell therapy for solid tumor patients for a Phase I clinical trial.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 17, 2024

                          Lead Product(s) : TCR-T Cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Charles River Laboratories, Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank